GlassScriptPhysician profile
Steven Jonathan Williams
NPI 1316350135
$667.22
in general payments reported to CMS, 2019-2025
23 companies · $101 in 2025
The $101 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.16 · 2021: $68.94 · 2022: $216 · 2023: $153 · 2024: $111 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $365.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $73.20 | 2022 | |
| Organon LLC | $65.26 | 2021-2023 | Nexplanon |
| Ironshore Pharmaceuticals INC. | $55.21 | 2024 | |
| Lilly USA, LLC | $48.71 | 2023 | Jardiance |
| Corcept Therapeutics | $41.63 | 2024 | Korlym |
| Cranial Technologies, INC | $39.82 | 2023-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $36.61 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $29.94 | 2021-2022 | |
| Novo Nordisk INC | $28.63 | 2023-2024 | Wegovy |
| Supernus Pharmaceuticals, INC. | $27.62 | 2021 | |
| Merck Sharp & Dohme LLC | $24.56 | 2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $23.44 | 2025 | |
| Tris Pharma INC | $21.28 | 2025 | Quillivant |
| Ascendis Pharma Endocrinology INC | $18.38 | 2022 | |
| Impel Pharmaceuticals INC. | $17.80 | 2023 | Trudhesa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.16 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.73 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.60 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.03 | 2023 | Horizant |
| Bayer Healthcare Pharmaceuticals INC. | $13.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.63 | 2022 | |
| Bausch Health US, LLC | $13.53 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.